Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? [Yahoo! Finance]
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Yahoo! Finance
Conference, AbCellera Biologics Inc. (NASDAQ:ABCL) reaffirmed its strategic evolution into a company focused on developing clinical assets. The company will no longer operate under a partnership model but will develop its own assets backed by a strong financial position. Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? Photo by CDC on Unsplash With over $500 million in cash and equivalents, AbCellera is focused on the development of ABCL635, a first-in-class antibody medicine for the non-hormonal treatment of moderate to severe menopausal hot flashes. The company is also working on ABCL575, an antibody for the treatment of moderate-to-severe atopic dermatitis (AD). Even as the company continues to work on its clinical assets, strategic partnerships with big Pharma, including Eli Lilly and AbbVie, are crucial. The internal clinical assets are only seen as a presale activity for future licensing. Amid the new strategic focus,
Show less
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- Short sales on the TSX: Where are the sellers as software stocks tumble? [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- AbCellera Biologics Inc. (ABCL): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Reassessing AbCellera Biologics (ABCL) After A Sharp 16.8% Weekly Share Price Drop [Yahoo! Finance]Yahoo! Finance
- AbCellera to Report Full Year 2025 Financial Results on February 24, 2026Business Wire
- AbCellera Biologics (NASDAQ:ABCL) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ABCL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
ABCL
Earnings
- 11/6/25 - Miss
ABCL
Sec Filings
- 1/14/26 - Form 8-K
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- ABCL's page on the SEC website